Cervomed Inc CRVO

$2.24 -0.01 (-0.44%)

Valuation

Market cap
33,867,000
Revenue TTM
$4,010,000
Net income TTM
$-26,970,000
PE ratio
0.00
Forward PE
—
Profit margin
-672.57%
Debt to equity
0.00

Trading

Volume
98,700
Avg volume
281,390
Day's range
$2.22 – $2.30
Shares out
15,119,000
Stochastic %K
8%
Beta
-0.75
Analysts
Strong Sell
Price target
$18.00

Price

Company profile

CervoMed Inc., a clinical-stage biotechnology company, engages in the development and commercialization of treatments for age-related neurologic disorders. The company is developing neflamapimod, an orally administered small molecule drug that crosses the blood–brain barrier and inhibits the enzyme p38a. Neflamapimod has the potential to reverse synaptic dysfunction, improve neuron health, and slow or prevent disease...

Show more

CervoMed Inc., a clinical-stage biotechnology company, engages in the development and commercialization of treatments for age-related neurologic disorders. The company is developing neflamapimod, an orally administered small molecule drug that crosses the blood–brain barrier and inhibits the enzyme p38a. Neflamapimod has the potential to reverse synaptic dysfunction, improve neuron health, and slow or prevent disease progression. Neflamapimod is currently in clinical development for the treatment of dementia with Lewy bodies, non-fluent variant primary progressive aphasia, amyotrophic lateral sclerosis, and amyotrophic lateral sclerosis. CervoMed Inc. was founded in 2010 and is headquartered in Boston, Massachusetts.

Industry
Biotechnology
Sector
Healthcare
Phone
617 744 4400
Website
https://www.cervomed.com
Address
20 Park Plaza, Suite 424, Boston, United States

Latest news

Stocktwits

5layer Oct 16, 2:47 PM 0 replies
walker7782 Oct 16, 11:29 AM
$CRVO Not a long but wanted to provide clarity. “Shorts” aren’t in control here. Funds like Sabby act as financers of last resort: they provide guaranteed, immediate capital when public markets are closed to the company, but extract punitive structural terms—deeply discounted shares, heavy warrant coverage, and reset provisions—that protect the fund while shifting dilution and price suppression onto common shareholders. A PIPE (Private Investment in Public Equity) fund buys discounted shares/warrants directly from an issuer. Sabby suppresses CRVO via convertible arbitrage: shorting common stock into rallies to lock gains, then covering risk-free using discounted shares/warrants, capping upside at warrant walls. CRVO management is complicit and knew this outcome going in. They’re pretty much a Wall Street loan shark. A big run will be an uphill battle here. Wishing longs all the best though! It’s just important to understand what you’re up against.
3 replies
BPler Oct 16, 8:07 AM
$CRVO Mentioning "Some studies have already started to capture audio, including a phase 2 trial studying the drug neflamapimod in patients with PPA, which has gathered voice recordings to analyze for linguistic and acoustic metrics." https://neurologytoday.aan.com/doi/10.1097/01.wnt.0001288804.23898.57
0 replies
Dagda Oct 15, 12:47 PM
$CRVO Hi Everyone, Many of us are long-term holders here and I was just wondering how you are all feeling about CRVO's potential over the next three years or so. My feeling is that concrete acquisition of a partner for Phase Three will restore investor sentiment in the company, and pave the way for commercial success by 2030/31.
3 replies
gboyce1220 Oct 14, 9:19 PM
$CRVO Many ppl suffer across the world(3.9M) with early onset dementia in many forms. They would do anything to slow the progression and enjoy more meaningful and productive time with family and their lives. $CRVO only needs the drug to slow the progression and that’s a plentiful market to make $. If it improves speech & motor that’s just xtra gravy.
0 replies
janed102 Oct 14, 7:00 PM
$CRVO sinking ship
1 replies
walker7782 Oct 14, 5:33 PM
$CRVO Couldn’t say no to those prices, zero liquidity means gut checking drops to hunt stop losses are easy. Added at 2.17.
0 replies
Disinformation_Consumer Oct 14, 5:32 PM
$CRVO theyre probably gonna go bankrupt at this rate.
0 replies